Press Releases

Month Year

Investor Alerts

Apr 8, 2014

Karyopharm Therapeutics to Present at 13th Annual Needham Healthcare Conference

NATICK, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Mar 5, 2014

Karyopharm Therapeutics Reports 2013 Year-End Financial Results and Provides Update on Clinical Development Plans

NATICK, Mass., March 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Feb 27, 2014

Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore

NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Feb 26, 2014

Karyopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting

NATICK, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Feb 6, 2014

Karyopharm Therapeutics to Present at Upcoming Healthcare Conferences in February

NATICK, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
Jan 22, 2014

Karyopharm Therapeutics Presents Clinical Data on Selinexor (KPT-330) in Colorectal Cancer From Ongoing Phase 1 Study and Preclinical Data on Novel PAK4 Inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium

- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients -

NATICK, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Jan 14, 2014

Karyopharm Therapeutics Announces Data Presentations at American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium

NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Jan 8, 2014

Karyopharm Therapeutics Announces Award of Grant From National Multiple Sclerosis Society to Further Develop Selective Inhibitors of Nuclear Export (SINE) Compounds

NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
Dec 20, 2013

Karyopharm Therapeutics Added to Russell 3000(R) and Russell 2000(R) Indexes

NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Dec 11, 2013

Karyopharm Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering

NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...

Show per page

Click here to print this page.
Click here to send us an email.
Click here to subscribe to RSS Feed.